PE20050358A1 - Composiciones referidas a inhibidores de canales ionicos regulados por voltaje - Google Patents
Composiciones referidas a inhibidores de canales ionicos regulados por voltajeInfo
- Publication number
- PE20050358A1 PE20050358A1 PE2004000774A PE2004000774A PE20050358A1 PE 20050358 A1 PE20050358 A1 PE 20050358A1 PE 2004000774 A PE2004000774 A PE 2004000774A PE 2004000774 A PE2004000774 A PE 2004000774A PE 20050358 A1 PE20050358 A1 PE 20050358A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- ion channels
- referred
- voltage regulated
- compositions referred
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 2
- PXXNTAGJWPJAGM-VCOUNFBDSA-N Decaline Chemical compound C=1([C@@H]2C3)C=C(OC)C(OC)=CC=1OC(C=C1)=CC=C1CCC(=O)O[C@H]3C[C@H]1N2CCCC1 PXXNTAGJWPJAGM-VCOUNFBDSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- BJGKRICBCYVRDX-UHFFFAOYSA-N ethyl 4-(2,4-dichlorophenoxy)butanoate Chemical compound CCOC(=O)CCCOC1=CC=C(Cl)C=C1Cl BJGKRICBCYVRDX-UHFFFAOYSA-N 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
- C07D209/92—Naphthostyrils
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I-A DONDE RN ES H, C1-C4 ALIIFATICO OPCIONALMENTE SUSTITUIDO; X1 ES O, S O NRX; X2 ES C1-C3 ALIFATICO OPCIONALMENTE SUSTITUIDO; p ES 0-1; Z ES i, ii, ENTRE OTROS; T ES ANILLO BICICLICO O TRICICLICO, AROMATICO O NO, DE 8-14 MIEMBROS TAL COMO NAFTILO, TETRALINA, O DECALINA. SON COMPUESTOS PREFERIDOS: 4-(2,4-DICLOROFENOXI)-BUTIRATO DE ETILO; 5,7-DICLORO-INDOL-2-IL-N-[4-(TIADIAZOL-2-ILSULFAMOIL)-FENIL]AMIDA Y N-[4-(TIAZOL-2-ILSULFAMOIL)-FENIL]-2-(4-FLUOROFENOXI)-ACETAMIDA; ENTRE OTROS. TAMBIEN REFERIDO A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS COMPUESTOS QUE SON UTILES PARA EL TRATAMIENTO DE DOLORES NEUROPATICOS E INTRATABLES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49365903P | 2003-08-08 | 2003-08-08 | |
US58471704P | 2004-07-01 | 2004-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050358A1 true PE20050358A1 (es) | 2005-05-16 |
Family
ID=34138760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000774A PE20050358A1 (es) | 2003-08-08 | 2004-08-09 | Composiciones referidas a inhibidores de canales ionicos regulados por voltaje |
Country Status (13)
Country | Link |
---|---|
US (3) | US8202861B2 (es) |
EP (3) | EP1673357A2 (es) |
JP (2) | JP2007501804A (es) |
KR (1) | KR20060073930A (es) |
AR (1) | AR045238A1 (es) |
AU (1) | AU2004263179B8 (es) |
CA (1) | CA2539227A1 (es) |
IL (1) | IL173602A0 (es) |
NO (1) | NO20061092L (es) |
NZ (2) | NZ579370A (es) |
PE (1) | PE20050358A1 (es) |
TW (1) | TW200524888A (es) |
WO (1) | WO2005013914A2 (es) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
KR100860581B1 (ko) | 2002-05-18 | 2008-09-26 | 엘지전자 주식회사 | 멀티캐스트 데이터 전송 방법 |
KR20030097559A (ko) | 2002-06-22 | 2003-12-31 | 엘지전자 주식회사 | 무선이동통신 시스템의 멀티미디어 서비스 방법 |
EP1673357A2 (en) * | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
KR100595646B1 (ko) | 2004-01-09 | 2006-07-03 | 엘지전자 주식회사 | Mbms서비스를 제공하는 무선통신 시스템 |
US7507860B2 (en) | 2004-04-13 | 2009-03-24 | Pfizer Inc. | Androgen modulators |
JP2007533726A (ja) | 2004-04-22 | 2007-11-22 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲンモジュレーター |
MXPA06015169A (es) | 2004-07-08 | 2007-08-21 | Warner Lambert Co | Moduladores de androgenos. |
US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
WO2006038680A1 (ja) * | 2004-10-01 | 2006-04-13 | Banyu Pharmaceutical Co.,Ltd | 2-アリールカルボキサミド-含窒素複素環化合物 |
ATE544748T1 (de) | 2004-12-28 | 2012-02-15 | Kinex Pharmaceuticals Llc | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
EP1857444A4 (en) * | 2005-03-10 | 2009-04-29 | Kyoto Pharma Ind | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICAL USE THEREOF |
WO2006095822A1 (ja) * | 2005-03-11 | 2006-09-14 | Ono Pharmaceutical Co., Ltd. | スルホンアミド化合物およびその医薬 |
US20090264533A1 (en) * | 2005-03-30 | 2009-10-22 | Richard Neubig | Methods and Compositions for Modulating RHO-Mediated Gene Transcription |
CA2603926A1 (en) * | 2005-04-08 | 2006-10-12 | Neuromed Pharmaceuticals Ltd. | Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
CN101218226A (zh) | 2005-05-16 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
KR20080019693A (ko) * | 2005-06-09 | 2008-03-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 인단 유도체 |
US7615569B2 (en) * | 2005-08-16 | 2009-11-10 | Icagen, Inc. | Inhibitors of ion channels |
NZ567132A (en) * | 2005-09-09 | 2011-12-22 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
CN101365690A (zh) * | 2005-10-12 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道调控剂的联苯衍生物 |
CN101331115A (zh) * | 2005-10-21 | 2008-12-24 | 沃泰克斯药物股份有限公司 | 调控离子通道的衍生物 |
CA2628312A1 (en) | 2005-11-02 | 2007-05-18 | Icagen, Inc. | Inhibitors of ion channels |
NZ569694A (en) * | 2005-12-21 | 2011-06-30 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels |
MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
JP5564251B2 (ja) | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するためのビアリール組成物および方法 |
EP2054397B1 (en) | 2006-08-16 | 2015-10-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
WO2008022286A2 (en) | 2006-08-16 | 2008-02-21 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
CA2668859A1 (en) * | 2006-11-07 | 2008-05-15 | Proteologics Ltd. | Pyrimidine derivatives as posh and posh-ap inhibitors |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
WO2008098239A2 (en) * | 2007-02-09 | 2008-08-14 | Emory University | Paramyxovirus family inhibitors and methods of use thereof |
US8357711B2 (en) * | 2007-03-23 | 2013-01-22 | Pfizer Limited | Heterocyclic sulfonamides as inhibitors of ion channels |
SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
WO2008130321A2 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain |
WO2008130319A2 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain |
WO2008130323A1 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain |
WO2008130322A1 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel 5-heterocyclyl-chromane derivatives for the treatment of pain |
US8193194B2 (en) | 2007-05-25 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
WO2009009041A2 (en) | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
EP2175728B1 (en) * | 2007-07-13 | 2014-09-10 | Icagen, Inc. | Sodium channel inhibitors |
WO2009016081A2 (en) * | 2007-08-02 | 2009-02-05 | Actar Ab | Benzoind0l-2-one derivatives for use in therapy |
US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
CA2701766A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
AU2008310663A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
EP2220080B1 (en) * | 2007-11-13 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
AU2008321137A1 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
CN101565418B (zh) * | 2008-04-23 | 2011-09-28 | 华东理工大学 | 酰胺衍生物及其用途 |
US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
WO2010002956A2 (en) * | 2008-07-01 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
WO2010033824A1 (en) * | 2008-09-19 | 2010-03-25 | Icagen, Inc. | Sulfonamide derivatives as inhibitors of ion channels |
WO2010035166A1 (en) * | 2008-09-23 | 2010-04-01 | Pfizer Limited | Benzamide derivatives |
BRPI1006128A2 (pt) * | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
EP2558085B1 (en) | 2010-04-16 | 2017-08-30 | Athenex, Inc. | Compositions and methods for the prevention and treatment of cancer |
JP5855095B2 (ja) | 2010-06-07 | 2016-02-09 | ノボメディックス,エルエルシーNovomedix,Llc | フラニル化合物およびその使用 |
JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドPfizer Limited | 化合物 |
US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
EP2593432B1 (en) | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
US9340590B2 (en) | 2011-03-16 | 2016-05-17 | Amgen Inc. | Potent and selective inhibitors of NaV1.3 and NaV1.7 |
WO2013009799A1 (en) * | 2011-07-11 | 2013-01-17 | Beth Israel Deaconess Medical Center, Inc. | Vitamin d receptor agonists and uses thereof |
EP2771324B1 (en) | 2011-10-24 | 2017-02-01 | Emory University | Myxovirus therapeutics, compounds, and uses related thereto |
BR112014010271A2 (pt) | 2011-10-31 | 2017-04-18 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
EP2791108B1 (en) * | 2011-12-15 | 2016-07-27 | Pfizer Limited | Sulfonamide derivatives |
WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
WO2013102826A1 (en) | 2012-01-04 | 2013-07-11 | Pfizer Limited | N-aminosulfonyl benzamides |
CA2878478A1 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
SI2890680T1 (en) | 2012-08-30 | 2018-08-31 | Athenex, Inc. Conventus Building | N- (3-FLUOROBENZYL) -2- (5- (4-MORFOLINOPHENYL) PIRIDIN-2-IL) ACETAMIDE AS PROTEIN TIROZINE KINASE PROTECTORS |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
MY177422A (en) | 2012-10-15 | 2020-09-15 | Dae Woong Pharma | Sodium channel blockers, preparation method thereof and use thereof |
EP2951168B1 (en) * | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
UY35288A (es) | 2013-01-31 | 2014-08-29 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
US9636418B2 (en) | 2013-03-12 | 2017-05-02 | Amgen Inc. | Potent and selective inhibitors of NAV1.7 |
WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
RU2015143834A (ru) | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
HUE037876T2 (hu) | 2013-07-19 | 2018-09-28 | Vertex Pharma | Szulfonamidok mint nátriumcsatorna-modulátorok |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
AP2016009287A0 (en) * | 2013-12-13 | 2016-06-30 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
CN105130970B (zh) * | 2014-05-30 | 2019-06-25 | 中国人民解放军军事医学科学院毒物药物研究所 | N-磺酰基高丝氨酸内酯类衍生物、其制备方法和用途 |
EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
KR20180008761A (ko) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | 치환된 벤즈아미드 및 이의 이용 방법 |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
EP3368509A4 (en) * | 2015-10-30 | 2019-05-01 | Trillium Therapeutics Inc. | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS |
WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
AU2016370554B2 (en) * | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
CA3008614A1 (en) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
CN109526219B (zh) | 2016-05-20 | 2021-03-12 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
MX2019004232A (es) * | 2016-10-17 | 2019-08-01 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos. |
BR112019011121A2 (pt) | 2016-12-09 | 2019-10-01 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
ES2927712T3 (es) | 2017-05-16 | 2022-11-10 | Vertex Pharma | Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio |
EP3412651A1 (en) | 2017-06-06 | 2018-12-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of rac1 and uses thereof for inducing bronchodilatation |
EP3412652A1 (en) | 2017-06-06 | 2018-12-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of rac1 and uses thereof for treating cancers |
JP2019099550A (ja) * | 2017-12-07 | 2019-06-24 | 学校法人兵庫医科大学 | スクロース吸収阻害剤、ChREBP阻害剤およびその利用 |
CA3091012A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
WO2019165290A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
SG11202100137TA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
CR20210099A (es) | 2018-08-31 | 2021-06-24 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
CN113677334B (zh) * | 2019-02-01 | 2024-04-09 | 马歇尔大学科研协会 | 瞬时受体电位melastatin 8(trpm8)拮抗剂和相关方法 |
US20220177422A1 (en) * | 2019-04-02 | 2022-06-09 | The University Of Chicago | Remodilins for airway remodeling and organ fibrosis |
WO2020254946A1 (en) | 2019-06-18 | 2020-12-24 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2430051A (en) * | 1944-08-16 | 1947-11-04 | Hoffmann La Roche | Soluble sulfanilamide derivatives and process of preparing them |
FR1537695A (fr) * | 1967-02-23 | 1968-08-30 | Ferlux | Nouvelles chromones carbonamides n-phénylsulfonamidées et procédé pour leur fabrication |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5360802A (en) * | 1992-05-11 | 1994-11-01 | Merck Sharpe & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
AU1924099A (en) | 1997-12-18 | 1999-07-05 | Lyonnaise Industrielle Pharmaceutique (Lipha) | Piperazine derivatives useful as hypoglycemic agents |
WO1999051587A1 (fr) * | 1998-04-01 | 1999-10-14 | Ono Pharmaceutical Co., Ltd. | Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif |
ATE339406T1 (de) * | 1999-09-23 | 2006-10-15 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
FI116940B (fi) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
CA2455754A1 (en) * | 2001-07-31 | 2003-02-20 | Bayer Healthcare Ag | Amine derivatives |
SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
EP1673357A2 (en) * | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
-
2004
- 2004-08-09 EP EP04780632A patent/EP1673357A2/en not_active Withdrawn
- 2004-08-09 NZ NZ579370A patent/NZ579370A/en not_active IP Right Cessation
- 2004-08-09 EP EP10185726A patent/EP2332912A1/en not_active Withdrawn
- 2004-08-09 PE PE2004000774A patent/PE20050358A1/es not_active Application Discontinuation
- 2004-08-09 CA CA002539227A patent/CA2539227A1/en not_active Abandoned
- 2004-08-09 KR KR1020067002746A patent/KR20060073930A/ko not_active Application Discontinuation
- 2004-08-09 AR ARP040102855A patent/AR045238A1/es unknown
- 2004-08-09 NZ NZ545710A patent/NZ545710A/en not_active IP Right Cessation
- 2004-08-09 EP EP10185719A patent/EP2327701A1/en not_active Withdrawn
- 2004-08-09 US US10/914,988 patent/US8202861B2/en active Active
- 2004-08-09 WO PCT/US2004/025827 patent/WO2005013914A2/en active Application Filing
- 2004-08-09 JP JP2006522803A patent/JP2007501804A/ja active Pending
- 2004-08-09 TW TW093123829A patent/TW200524888A/zh unknown
- 2004-08-09 AU AU2004263179A patent/AU2004263179B8/en not_active Ceased
-
2006
- 2006-02-08 IL IL173602A patent/IL173602A0/en unknown
- 2006-03-07 NO NO20061092A patent/NO20061092L/no not_active Application Discontinuation
-
2010
- 2010-11-24 JP JP2010261862A patent/JP2011032294A/ja not_active Withdrawn
-
2012
- 2012-05-23 US US13/478,538 patent/US8309543B2/en active Active
- 2012-10-26 US US13/661,337 patent/US20130184258A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ545710A (en) | 2010-02-26 |
TW200524888A (en) | 2005-08-01 |
WO2005013914A2 (en) | 2005-02-17 |
AU2004263179A8 (en) | 2011-07-14 |
US8309543B2 (en) | 2012-11-13 |
EP2327701A1 (en) | 2011-06-01 |
EP1673357A2 (en) | 2006-06-28 |
CA2539227A1 (en) | 2005-02-17 |
AR045238A1 (es) | 2005-10-19 |
WO2005013914A3 (en) | 2005-07-21 |
US20130184258A1 (en) | 2013-07-18 |
US20120238578A1 (en) | 2012-09-20 |
US8202861B2 (en) | 2012-06-19 |
NO20061092L (no) | 2006-04-27 |
US20050137190A1 (en) | 2005-06-23 |
JP2011032294A (ja) | 2011-02-17 |
AU2004263179B2 (en) | 2011-06-30 |
AU2004263179A1 (en) | 2005-02-17 |
AU2004263179B8 (en) | 2011-07-14 |
EP2332912A1 (en) | 2011-06-15 |
JP2007501804A (ja) | 2007-02-01 |
WO2005013914A8 (en) | 2006-09-28 |
IL173602A0 (en) | 2006-07-05 |
KR20060073930A (ko) | 2006-06-29 |
NZ579370A (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050358A1 (es) | Composiciones referidas a inhibidores de canales ionicos regulados por voltaje | |
MX2008001528A (es) | Inhibidores de serina proteasas. | |
PA8610801A1 (es) | Compuestos de aril o heteroaril amida | |
TN2011000252A1 (fr) | Lactames servant d'inhibiteurs de beta-secretase | |
MY145460A (en) | Biaryl ether urea compounds | |
UY27740A1 (es) | Nuevos compuestos | |
AR048973A1 (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas | |
UY29919A1 (es) | Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones | |
DOP2004000888A (es) | 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes | |
PE20050130A1 (es) | Compuestos organicos | |
CA2495967A1 (fr) | Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent | |
UY24409A1 (es) | Inhibidores de la matriz metaloproteasa | |
BRPI0410705A (pt) | forma cristalina de agonista de receptor 2 adrenérgico | |
MY145981A (en) | Method and compositions for attracting mosquitoes employing (r)-(-) isomers of 1-alken- 3-ols | |
MA27517A1 (fr) | Nouveau procede de synthese du (7-methoxy-1-naphtyl)acetonitrile et application a la synthese de l'agomelatine | |
ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
AR033335A1 (es) | Compuestos de acidos 3-propil gama aminobutirico mono y di sustituidos, composicion farmaceutica que los comprende y su uso para fabricar dicha composicion | |
CO6382118A2 (es) | Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio | |
MX2007001626A (es) | Agentes anti-inflamatorios. | |
TW200512201A (en) | New heterocyclic amides | |
ES8502673A1 (es) | Procedimiento para preparar compuestos de n-(2-(fenilmetilen)cicloalquil) aminas libres. desglose de la patente n 519.331. | |
CL2008003358A1 (es) | Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos. | |
Wrobleski et al. | Cyclobutane derivatives as potent NK1 selective antagonists | |
BRPI0409013A (pt) | processos para preparação de um produto de reação, de uma composição farmacêutica, de uma composição agroquìmica, de uma composição de limpeza, de uma composição de tinta e de um refrigerador ou lubrificante | |
MX2018006472A (es) | Mejoras en o relacionadas con compuestos organicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |